首页> 外文期刊>Japanese journal of clinical oncology. >Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.
【24h】

Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.

机译:Survivin和Smac基因的表达而不是livin是非小细胞肺癌术后接受辅助化疗的患者的预后指标。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Survivin and livin, which are members of the inhibitor of apoptosis protein family, regulate both programmed cell death and proliferation. Second mitochondria-derived activator of caspase is thought to regulate apoptosis by antagonizing inhibitor of apoptosis protein. These gene expressions are regarded as prognostic markers in some malignancies. However, result in previous studies of the association of these gene expressions with prognosis of patients with non-small cell lung cancer remains contradictory. METHODS: Survivin, livin and second mitochondria-derived activator of caspase mRNA was detected by semi-quantitative reverse transcriptase-polymerase chain reaction in surgical resected tumor specimen from 66 non-small cell lung patients who received adjuvant platinum-based chemotherapy. RESULTS: Results showed that patients with survivin high expression had significantly shorter tumor-free survival (P = 0.012) and overall survival (P = 0.007) than those with survivin low expression. There was a significant association of second mitochondria-derived activator of caspase high expression in non-small cell lung cancer tissue with longer tumor-free survival (P = 0.021) and overall survival (P = 0.0013). However, livin mRNA expression level had no impact on the tumor-free survival and overall survival of the patients. In multivariate analyses, survivin mRNA high expression (P = 0.033 and P = 0.024) and advanced pathologic stage (P = 0.009 and P = 0.008) were the factors which independently predicted a worse tumor-free survival and overall survival. CONCLUSIONS: Our data suggest that assessment of survivin and second mitochondria-derived activator of caspase mRNA expression may be useful for predicting survival in non-small cell lung cancer patients receiving platinum-based chemotherapy after surgical resection and can provide valuable information for deciding better therapy strategy.
机译:目的:Survivin和livin是凋亡蛋白家族抑制剂的成员,可调节程序性细胞死亡和增殖。人们认为第二种线粒体衍生的caspase激活剂通过拮抗凋亡蛋白抑制剂来调节凋亡。这些基因表达被认为是某些恶性肿瘤的预后标志物。然而,先前关于这些基因表达与非小细胞肺癌患者预后的关系的研究结果仍然是矛盾的。方法:通过半定量逆转录酶-聚合酶链反应,在66例接受了铂类辅助化疗的非小细胞肺癌患者的手术切除肿瘤标本中,通过半定量逆转录酶-聚合酶链反应检测了Survivin,livin和第二个线粒体衍生的caspase mRNA激活剂。结果:结果显示,高表达survivin的患者的无肿瘤生存期(P = 0.012)和总生存期(P = 0.007)明显低于低表达的患者。在非小细胞肺癌组织中,第二个线粒体衍生的caspase激活因子在非小细胞肺癌生存期较长(P = 0.021)和总生存期(P = 0.0013)的显着相关。但是,livin mRNA表达水平对患者的无肿瘤生存期和总体生存期没有影响。在多变量分析中,survivin mRNA高表达(P = 0.033和P = 0.024)和病理晚期(P = 0.009和P = 0.008)是独立预测较差的无肿瘤生存期和总生存期的因素。结论:我们的数据表明,评估survivin和第二个线粒体衍生的caspase mRNA激活因子可能有助于预测手术切除后接受铂类化学疗法的非小细胞肺癌患者的生存,并可以为确定更好的治疗方法提供有价值的信息战略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号